BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 23269354)

  • 1. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
    Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
    Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
    J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas.
    Sundov D; Petric Mise B; Mrklic I; Bacic B; Vrdoljak E; Tomic S
    Neoplasma; 2017; 64(2):289-298. PubMed ID: 28052682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas.
    Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS
    Ann Oncol; 2004 Oct; 15(10):1535-42. PubMed ID: 15367415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.
    Cho EY; Choi Y; Chae SW; Sohn JH; Ahn GH
    Pathol Int; 2006 Feb; 56(2):62-70. PubMed ID: 16445817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
    Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
    Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
    Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
    J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
    Mell LK; Meyer JJ; Tretiakova M; Khramtsov A; Gong C; Yamada SD; Montag AG; Mundt AJ
    Clin Cancer Res; 2004 Aug; 10(16):5546-53. PubMed ID: 15328195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis.
    Dian D; Brüning A; Mylonas I
    Arch Gynecol Obstet; 2011 Aug; 284(2):437-43. PubMed ID: 20803206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB-3 predicts survival in ovarian cancer.
    Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
    J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.
    Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Janssen EA; Baak JP; Rollason TP
    Int J Gynecol Pathol; 2008 Apr; 27(2):191-8. PubMed ID: 18317224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer.
    Lin Q; Li M; Shen ZY; Xiong LW; Pan XF; Gen JF; Bao GL; Sha HF; Feng JX; Ji CY; Chen M
    Jpn J Clin Oncol; 2010 Jul; 40(7):670-6. PubMed ID: 20382636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.